A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

AstraZeneca1,000 enrolled

Overview

To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Bronchial Asthma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept Exclusion Criteria: * None

Locations (1)

Research Site

London, United Kingdom

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.